不同药物治疗慢性阻塞性肺疾病急性加重期的价值研究

Study on the Value of Different Drugs in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

目的不同药物治疗慢性阻塞性肺疾病急性加重期的价值研究。方法以2018年7月—2020年5月为时间段,将于我院接受治疗的98例慢性阻塞性肺疾病急性加重期患者纳入本次研究,通过盲抽双色球的方式分别归纳为对照组(49例患者)与观察组(49例)患者;对照组患者院内的治疗方案为特布他林,观察组患者院内的治疗方案为特布他林+布地奈德+复方异丙托溴铵;对比分析两组患者治疗前后的肺功能指标、血气指标。结果在肺功能指标方面,治疗前,两组患者的FEV1、FVC、FEV1/FVC基本等同,数据组间对比不可见统计学差异(P>0.05),而治疗后,观察组患者的FEV1、FVC、FEV1/FVC均高于对照组患者,差异有统计学意义(P<0.05);在血气指标方面,治疗前,两组患者的PaO2与PaCO2基本等同,差异无统计学意义(P>0.05),而治疗后,观察组患者的PaO2高于对照组,PaCO2低于对照组,差异有统计学意义(P<0.05)。结论慢性阻塞性肺疾病急性加重期患者临床联合应用特布他林、布地奈德与复方异丙托溴铵,可以有效改善其血气指标与肺功能,有利于患者获取更好的临床治疗效果。

Objective Different drugs for the treatment of acute exacerbation of chronic obstructive pulmonary disease period value research.Methods In July 2018-May 2020 for period of time,will be treated in our hospital during the period of 98 cases of chronic obstructive pulmonary disease in patients with acute aggravating period included in this study,through the way of blind draw the double chromosphere respectively summarized as the control group(49 cases)and observation group(49 cases);Control group patients nosocomial treatment for terbutaline,observation group of patients with nosocomial treatment for terbutaline+budesonide+compound isopropyl Joe bromide;Analysis of two groups of patients before and after treatment and clinical treatment effect of lung function index,blood gas index,the incidence of adverse reactions.Results In terms of pulmonary function indexes,before treatment,FEV1,FVC and FEV1/FVC of the two groups were basically the same,and there was no significant difference between the data groups(P>0.05).After treatment,FEV1,FVC and FEV1/FVC of the observation group were higher than those of the control group(P<0.05);In terms of blood gas indexes,before treatment,PaO2 and PaCO2 in the two groups were basically the same,and the difference was not statistically significant(P>0.05).After treatment,PaO2 in the observation group was higher than that in the control group,and PaCO2 was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion chronic obstructive pulmonary disease in patients with acute aggravating period of clinical combined use of terbutaline,budesonide and compound isopropyl bromide,can effectively improve the blood gas index and pulmonary function,can patients get better clinical therapeutic effect,and lower the risk of adverse reactions,realize the promoting effect on the early rehabilitation of patients,is worth to popularize and apply in the clinical practice.